icon- folder.gif   Conference Reports for NATAP  
 
  XVII International AIDS Conference
Mexico City
3-8 August 2008
Back grey_arrow_rt.gif
 
 
 
TMC278 (rilpivirine), an investigational next-generation NNRTI, demonstrates long-term efficacy and tolerability in ARV-naive patients: 96-week results of study C204
 
 
  Reported by Jules Levin
 
M Santoscoy,1 P Cahn,2 C Gonsalez,3 W Hao,4
A Pozniak,5 P Shalit,6 S Vanveggel,7 K Boven8
1Hospital Carlos Mac Gregor IMSS, Mexico City, Mexico; 2Hospital Juan A Fernández and Fundación Huesped, Buenos Aires, Argentina; 3Hospital das Clíncias, Pinheiros, Brazil; 4Beijing You’an Hospital, Beijing, China; 5Chelsea and Westminster NHS Foundation Trust and PKR/SSR, London, UK; 6Swedish Medical Center, Seattle, WA, USA; 7Tibotec BVBA, Mechelen, Belgium; 8Tibotec Inc., Yardley, PA, USA.
 
AUTHOR CONCLUSIONS
 
Once-daily oral TMC278 at all doses demonstrated a high response rate and sustained virologic response over 96 weeks
 
TMC278 was generally safe and well tolerated
 
Incidences of rash, nervous system- and psychiatric-related AEs and increase in lipids were significantly lower with TMC278 than with EFV
 
There were trends suggesting a favourable profile of TMC278 25mg compared with the higher dose groups
 
Both efficacy and safety of TMC278 were well maintained between 48 and 96 weeks
 
TMC278 is being further evaluated in Phase III trials at a dose of 25mg qd

NNRT-1.gif

log-2.gif

sustan-3.gif

tmc-4.gif

RMA-5.gif

serve-6.gif

EFV-7.gif

edc-8.gif